Richter Gedeon Vegyeszeti Gyar Nyrt represents strong values and a robust corporate philosophy. With a focus on pharmaceuticals and healthcare, Richter Gedeon aims to provide innovative solutions and improve the well-being of society. The company upholds integrity, ethics, and excellence in all its endeavors, ensuring high product quality and patient safety. Through continuous research and development, Richter Gedeon strives for scientific advancements and breakthrough therapies. Commitment to environmental sustainability and social responsibility is also an integral part of their corporate philosophy, contributing to a healthier and more sustainable future.

Richter Gedeon Vegyeszeti Gyar Nyrt, commonly known as Richter, is primarily present in several countries and regions. These include Hungary, its home country where it is headquartered in Budapest. Richter also has a significant presence in other European countries such as Romania, Poland, Czech Republic, Slovakia, and Russia. It has further expanded its operations to countries in Asia, including China and Vietnam. Additionally, Richter has a presence in the United States, where it has a subsidiary called Richter-Helm BioLogics.

Richter Gedeon Vegyeszeti Gyar Nyrt, a prominent pharmaceutical company, has achieved several significant milestones throughout its history. The company has established itself as a leader in the development and production of innovative medicines and healthcare products. Richter Gedeon Nyrt has successfully introduced numerous breakthrough drugs, addressing various therapeutic areas such as women's health, central nervous system disorders, and cardiovascular diseases. With a strong commitment to research and development, Richter Gedeon Nyrt has consistently focused on expanding its product portfolio and enhancing patient outcomes. This dedication to excellence has propelled the company to become a trusted name in the pharmaceutical industry.

Richter Gedeon Vegyészeti Gyár Nyrt., commonly known as Richter, is a Hungarian pharmaceutical company. Established in 1901, Richter has a rich history and extensive background in the pharmaceutical industry. With over a century of experience, the company has grown to become a leading player in Central and Eastern Europe, focusing on developing, manufacturing, and marketing innovative pharmaceutical products. Richter specializes in a wide range of therapeutic areas, including women's healthcare, central nervous system disorders, cardiovascular diseases, and gastroenterology. Through continuous research and development efforts, Richter strives to provide high-quality and affordable medications to improve the well-being of patients worldwide.

The main competitors of Richter Gedeon Vegyeszeti Gyar Nyrt in the market include pharmaceutical companies such as Novartis, Sanofi, and Roche. With its strong presence in the pharmaceutical industry, Richter Gedeon Vegyeszeti Gyar Nyrt competes against these global players in various therapeutic areas. The company's innovative products, extensive research and development efforts, and strategic partnerships enable it to withstand competition and maintain its market position. Richter Gedeon Vegyeszeti Gyar Nyrt continues to focus on delivering high-quality pharmaceutical solutions to meet the evolving needs of patients worldwide.

Richter Gedeon Vegyeszeti Gyar Nyrt is primarily active in the pharmaceutical industry.

The business model of Richter Gedeon Vegyeszeti Gyar Nyrt, also known as Richter, is focused on pharmaceutical and biotechnology research, development, and manufacturing. As a leading Hungarian company, Richter engages in the production of prescription drugs, over-the-counter medications, and active pharmaceutical ingredients (APIs). The company specializes in the fields of gynecology, central nervous system disorders, cardiovascular ailments, and osteoporosis. With a wide portfolio of innovative pharmaceutical products, Richter aims to improve the quality of life and well-being of patients worldwide. Combining their scientific expertise with cutting-edge technology, Richter strives to provide effective and safe healthcare solutions, contributing to the advancement of medicine globally.

Richter Gedeon Vegyeszeti Gyar Nyrt의 P/E 비율은 7.79입니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 P/S 비율은 2.3입니다.

Richter Gedeon Vegyeszeti Gyar Nyrt에 대한 AlleAktien 품질 점수는 9/10입니다.

예상되는 Richter Gedeon Vegyeszeti Gyar Nyrt 매출은 870.87 조. HUF입니다.

예상되는 Richter Gedeon Vegyeszeti Gyar Nyrt 이익은 256.63 조. HUF입니다.

Richter Gedeon Vegyeszeti Gyar Nyrt is a multinational pharmaceutical company based in Budapest, Hungary. The company specializes in the production of prescription and OTC medications, chemicals and active ingredients, as well as the development of generic products. The main business areas of Richter Gedeon are human pharmaceuticals, pharmaceutical chemistry, and biotechnology. The company operates research and development (R&D) in all areas and has state-of-the-art facilities in research, development, and production. The human pharmaceutical division includes the manufacture of drugs for the treatment of various diseases, such as schizophrenia, epilepsy, Parkinson's disease, migraines, gynecology, and gastroenterology. The products are sold worldwide and are available in various forms such as tablets, capsules, injections, and patches. The pharmaceutical chemistry division produces high-performance chemicals and active ingredients for the pharmaceutical industry. The company has been a leading player in this field for many years and collaborates closely with other pharmaceutical companies to develop cost-effective active agents. The range of products includes antibiotics, antidepressants, antithrombotics, antihypertensives, and hormones. The biotechnology division of Richter Gedeon focuses on the identification and development of proteins, peptides, and antibodies. The company invests heavily in R&D and has successfully developed a range of innovative biological products. The new products include MABp1, a biological medicine for the treatment of pain and inflammation, currently being tested in Phase III clinical trials, as well as a range of biosimilars, including the biosimilar version of Herceptin, a breast cancer medication. Richter Gedeon also has a strong presence in emerging markets. The company has subsidiaries in over 40 countries and has joint ventures with companies in China, Russia, and India. The company has also built a strong marketing and distribution network to sell its products worldwide. In Europe, Richter Gedeon is a market leader in several countries and focuses on expanding its presence in North America and Asia. In summary, Richter Gedeon Vegyeszeti Gyar Nyrt offers a wide range of pharmaceutical products, from drugs for the treatment of specific diseases to chemical agents, biotechnology products, and biosimilars. The company has a strong R&D base and invests in innovative products, joint ventures, and international expansion to strengthen its position in emerging markets.

Richter Gedeon Vegyeszeti Gyar Nyrt은(는) 연간 번의 배당을 통해 225.17 HUF의 배당금을 지급합니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 ISIN은 HU0000123096입니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 WKN은 A1W16N입니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 티커는 RICHTER.BD입니다.

지난 12개월 동안 Richter Gedeon Vegyeszeti Gyar Nyrt은(는) 391.32 HUF 의 배당금을 지급했습니다. 이는 약 3.62 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Richter Gedeon Vegyeszeti Gyar Nyrt은(는) 438.52 HUF의 배당금을 지급할 것으로 예상됩니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 현재 배당 수익률은 3.62 %입니다.

Richter Gedeon Vegyeszeti Gyar Nyrt은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Richter Gedeon Vegyeszeti Gyar Nyrt은(는) 지난 23년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 438.52 HUF의 배당금이 예상됩니다. 이는 배당수익률 4.05 %에 해당합니다.

Richter Gedeon Vegyeszeti Gyar Nyrt은 '건강' 섹터에 속합니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 마지막 배당금을 431.983 HUF만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Richter Gedeon Vegyeszeti Gyar Nyrt는 225.172 HUF를 배당금으로 지급했습니다.

Richter Gedeon Vegyeszeti Gyar Nyrt의 배당금은 HUF에 지급됩니다.